Results 251 to 260 of about 204,414 (356)
ABSTRACT Background As prostate cancer (PCa) remains one of the leading causes of cancer‐related death in men, it is important to develop effective therapeutic approaches for the treatment of metastatic PCa and to improve the accuracy of prognosis for aggressive tumors.
Anna‐Lena Lemster+9 more
wiley +1 more source
Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance. [PDF]
Li C, Cheng D, Li P.
europepmc +1 more source
ABSTRACT Background Prostate cancer (PCa) is the second most common solid tumor in men, and its incidence is strongly dependent on age. With the aging global population, this poses a significant medical and sociodemographic issue. As treatment options for castration‐resistant prostate cancer (CRPC) expand, the proportion of elderly patients with CRPC ...
Takafumi Fukushima+23 more
wiley +1 more source
PGC1α as a downstream effector of KDM5B promotes the progression of androgen receptor-positive and androgen receptor-negative prostate cancers. [PDF]
Teramoto Y+5 more
europepmc +1 more source
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) have significantly improved clinical outcomes for patients with metastatic prostate cancer (PC) but acquired ARPI resistance remains universal. Maximizing ARPI treatment duration is crucial to optimal clinical outcomes, but current clinical tools to detect acquired ARPI resistance ...
Marina Nasrin Sharifi+8 more
wiley +1 more source
Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone. [PDF]
Ingle JN+6 more
europepmc +1 more source
Late Bowel Symptoms in Long‐Term Survivors of Prostate Cancer Following Radiotherapy
ABSTRACT Background Despite advances in radiotherapy planning, some long‐term prostate cancer survivors experience persistent symptoms. Although overall quality of life appears comparable between patients treated with definitive and salvage radiotherapy and aligns with normative data, prostate‐specific deficits—particularly bowel symptoms—may persist ...
Isabella Gruber+2 more
wiley +1 more source
rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC. [PDF]
Chi KN+13 more
europepmc +1 more source
ABSTRACT Background N‐terminus 15 amino acid (MC16) of Annexin A1 (ANXA1) is an effective therapeutic target for tumors and tumor vasculature as it specifically localizes to the cell surface of tumor cells and tumor vascular endothelial cells. We identified the d‐type peptide (hpnevrs, dhp7) by mirror‐image phage display targeting l‐type MC16 and ...
Kai Ozaki+8 more
wiley +1 more source